3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Fluorouracil
12
Radiotherapy
8
Cisplatin
8
pembrolizumab
4
Papillomavirus Vaccines
4
Mitomycin
4
Irinotecan
4
Cyclophosphamide
4
Cetuximab
4
Light Coagulation
3
Interleukin-12 Subunit p35
3
Capecitabine
3
fludarabine phosphate
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Watchful Waiting
2
Vaccines
2
Trastuzumab
2
Surveys and Questionnaires
2
Radiation
2
Quality of Life
2
Paclitaxel
2
Oxaliplatin
2
Erlotinib Hydrochloride
2
Early Intervention, Educational
2
Carboplatin
2
Biopsy
2
toripalimab
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Anus Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled